What starts a compounded peptide order?
It starts with a single patient. Under section 503A of federal law, the FDA explains that a pharmacy may only compound a drug like this after receiving a valid patient-specific order from a licensed clinician. The pharmacy is not making stock to sell; it is making a medicine with your name on it.
That order comes after an evaluation. Your clinician decides that a peptide fits, chooses the dose and form, and sends the order to a licensed pharmacy. Compounded drugs are not FDA-approved, and the FDA’s compounding questions and answers note that the agency does not review their safety, effectiveness or quality before they are dispensed. Day-to-day oversight of 503A pharmacies sits mainly with state boards of pharmacy.
Where does the pharmacy get the raw peptide?
From a bulk ingredient supplier, under strict conditions. The FDA’s page on 503A bulk drug substances says the ingredient must have been made by an establishment registered with the FDA, must come with a valid certificate of analysis, and must meet one of three eligibility tests:
- it complies with a USP or National Formulary monograph, where one exists;
- it is a component of an FDA-approved drug, where no monograph exists; or
- it appears on the FDA’s 503A bulks list.
California adds its own checks for injectables. The Board of Pharmacy’s 2026 Lawbook requires every active ingredient in a sterile preparation to come from an FDA-registered facility with a certificate of analysis that names the manufacturer and its address, evaluated before use. It also bans using any ingredient labeled “not for human use” or “not for injectable use.”
How is an injectable peptide made sterile?
In a controlled cleanroom, by staff trained and tested in sterile technique. In California, a pharmacy may not compound sterile products at all without a separate sterile compounding license, and the board inspects the site before issuing or renewing it. Out-of-state pharmacies shipping sterile products into California need their own California sterile license.
The work follows USP Chapter 797, the national standard for sterile compounding, plus the state’s added rules on facilities, air and surface monitoring, garbing, cleaning and sterilization. The goal is simple to state and hard to do: an injectable that contains the right peptide, at the right strength, with no microbes and no bacterial toxins.
What testing happens before it reaches you?
Release testing is where a pharmacy product differs most from a research vial. California’s rules for sterile compounding include:
| Requirement | What it means for you |
|---|---|
| Endotoxin testing for injectables made from nonsterile ingredients | Bulk peptide powders are nonsterile, so the finished injectable must be checked for bacterial toxins, with results reviewed before it is released |
| Sterility or endotoxin testing when USP requires it | Results must be within USP limits and reviewed before the product is furnished |
| Beyond-use date limited by stability data | The date on your label cannot run past what the ingredient’s stability supports |
| Pharmacist responsibility | A named pharmacist answers for the product’s integrity, quality and labeled strength until its beyond-use date |
The rules make the pharmacist responsible for labeled strength without spelling out one potency test for every product. If potency testing matters to you, it is a reasonable question to ask the pharmacy or your provider. Once the vial reaches you, storage is your part of the chain; our guide to storing peptides and injectables covers it.
Why do only some peptides qualify?
Because eligibility depends on the ingredient, not on demand. As of October 2026:
| Peptide | Can a 503A pharmacy compound it? | Why |
|---|---|---|
| Sermorelin | Yes | Formerly FDA-approved as Geref; compounded today |
| Tesamorelin | No | Regulated as a biologic since March 2020, so only the FDA-approved product (Egrifta) is available |
| HCG (Pregnyl) | No | Also a biologic since 2020; see why compounded HCG disappeared |
| BPC-157, TB-500 | Unsettled | Off the FDA safety-concern list since April 2026; advisory committee backed them in July; no final rule |
| GHK-Cu | Unsettled | Off the same list; FDA review due by early 2027 |
| CJC-1295, ipamorelin, AOD-9604 | No | Not eligible for compounding |
Leaving the FDA’s list of substances with significant safety risks does not by itself make a peptide eligible, and that list still records the agency’s concerns about impurities and immune reactions. Our answer on CJC-1295 and ipamorelin explains why those two are off the table, and our answer on whether peptides are legal in California puts the state rules in context.
How Ultimate Male works with compounding pharmacies
Peptides in our peptide therapy program come from licensed U.S. compounding pharmacies, or as the FDA-approved product in the case of tesamorelin, and only for peptides that can be supplied lawfully. After labs and a one-on-one consultation, your medicine is shipped to you or kept at the clinic, and your first injection is shown in person.
If you want to know more about the two pharmacy types, our explainer on 503A and 503B pharmacies compares them, and our answer on whether research peptides are safe shows what happens without any of these steps.
